secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2024-05-30T23:59:59+00:00
Accession:  0001193125-24-150323
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Taysha Gene Therapies holds 2024 annual meeting; directors elected and auditor ratified
--------------------------------------------------------------------------------

- Shareholders elect Sean Stalfort and Alison Long as directors until 2027.
- Deloitte & Touche LLP ratified as independent auditor for FY2024.
- Approximately 80% of outstanding shares (149.6M of 187M) were represented at the meeting.
- Director votes: Stalfort 131.8M for, 287.6K withheld; Long 132.0M for, 77.5K withheld.
- Auditor ratification: 149.5M for, 60.4K against, 100.5K abstained; no broker non-votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312524150323/0001193125-24-150323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312524150323/d805768d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-150323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer